UnitedHealth, Edwards Lifesciences, First Citizens Bank And More: CNBC's 'Final Trades' - Edwards Lifesci

　　Jim Lebenthalof Cerity Partners hyped UnitedHealth Group IncorporatedUNH as a “solid” healthcare company in the latest edition of CNBC's “Halftime Report Final Trades.”

　　On July 9, Cantor Fitzgerald analyst Sarah James reiterated UnitedHealth with an Overweight rating and maintained a price target of $591.

　　Don't forget to check out our premarket coverage here.

　　Brian Belskiof BMO Capital Markets said First Citizens BancShares, Inc.FCNCA is a “great, great brand.”

　　First Citizens BancShares is expected to report its financial results for the quarter ended June 30, 2024, before the opening bell on Thursday, July 25. Analysts expect the company to report quarterly earnings at $44.57 per share on revenue of $2.33 billion.

　　Shannon Saccociaof NB Private Wealth named iShares U.S. Real Estate ETFIYR as her final trade.

　　On May 14, Ventas declared a second-quarter 2024 dividend of 45 cents per common share.

　　Joseph M. Terranovaof Virtus Investment Partners picked Edwards Lifesciences CorporationEW.

　　On June 3, Becton, Dickinson And CompanyBDX said it will acquire Edwards Lifesciences Corp's Critical Care product group, an advanced monitoring solutions provider, for $4.2 billion in cash.

　　Price Action:

• First Citizens BancShares shares gained 1.3% to close at $1,743.19 on Wednesday.
• UnitedHealth rose 1.8% to settle at $500.93 during Wednesday's session.
• iShares U.S. Real Estate ETF gained 0.8% on Wednesday.
• Edwards Lifesciences shares gained 0.3% to close at $93.78 during Wednesday's session.